Immutep (NASDAQ:IMMP) Share Price Crosses Below 50-Day Moving Average - Here's Why

Immutep Limited (NASDAQ:IMMP - Get Free Report) shares crossed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $1.72 and traded as low as $1.61. Immutep shares last traded at $1.68, with a volume of 59,932 shares trading hands.

Immutep Price Performance

The firm's 50 day simple moving average is $1.71 and its 200-day simple moving average is $1.90. The company has a quick ratio of 18.25, a current ratio of 18.25 and a debt-to-equity ratio of 0.01.

Institutional Investors Weigh In On Immutep

Several large investors have recently modified their holdings of IMMP. Fortitude Advisory Group L.L.C. acquired a new stake in Immutep during the 4th quarter worth $28,000. OLD Mission Capital LLC acquired a new stake in shares of Immutep during the fourth quarter worth about $36,000. Two Sigma Securities LLC purchased a new position in shares of Immutep during the fourth quarter worth about $74,000. ABC Arbitrage SA acquired a new position in Immutep in the 4th quarter valued at about $152,000. Finally, XY Capital Ltd lifted its position in Immutep by 52.0% during the 4th quarter. XY Capital Ltd now owns 164,655 shares of the biotechnology company's stock worth $357,000 after acquiring an additional 56,306 shares during the period. 2.32% of the stock is owned by institutional investors and hedge funds.

About Immutep

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.